What to bring and ask before PRP, the blood-based treatment

What to ask about the exam

Ask which tissue is most likely sore. A tendon, joint, nerve, or bursa, a small cushion beside a joint, can hurt in the same place. Your clinician may check strength, motion, and tender areas.

The clinician may use an X-ray or a different scan when a tear or joint wear seems possible. Mention any sudden pop, lost strength, fever, marked swelling, numbness, or recent fall. Those problems need attention before a planned PRP treatment is considered.

What to ask about PRP and recovery

PRP means platelet-rich plasma, made when staff draw your blood and separate its platelet-heavy layer in a spinning machine. That saved portion becomes the shot. Ask which tissue the needle will enter and how sore the area may feel afterward.

Get clear directions for activity, medicines, and whom to call with concerns. Ask when walking, reaching, or lifting may resume. Find out when the clinician will check you again and what care may follow if soreness remains.

What to ask about the full price

Ask for a written quote showing whether the exam, shot, guidance, and follow-up are included. Insurance coverage varies, and patients often pay for this care themselves. Don't use another person's coverage to judge your own.

Read payment terms apart from the medical choice. A lower price may cover less care, while a higher one doesn't prove better care. A clear quote lets you compare the same services.

What QC Kinetix can discuss with you

For soreness that hasn't eased, QC Kinetix can discuss biologic therapies, its term for care that starts with something from your body. Here, the named treatment is the PRP blood shot described above. Medical providers are clinic clinicians who examine you and read your health record before treatment.

They may discuss PRP as a natural pain treatment to consider before knee or hip surgery. Ask them to name each step and explain what happens on treatment day. No visit can promise a certain result, and you shouldn't have to guess about recovery or warning signs.

Sources

1. A placebo-controlled, double-blind randomized trial of 40 patients with chronic rotator cuff tendinopathy compared a single ultrasound-guided subacromial injection of 5 mL PRP with 5 mL saline, with both groups completing a 6-week standard exercise programme and follow-up to one year. PRP did not produce better outcomes than saline on any measure - a reminder that the exercise programme, not the injectate, carried the improvement.

   Kesikburun S, Tan AK, Yilmaz B, et al. — Platelet-rich plasma injections in the treatment of chronic rotator cuff tendinopathy: a randomized controlled trial with 1-year follow-up. American Journal of Sports Medicine, 2013. DOI: 10.1177/0363546513496542.

2. In a double-blind, placebo-controlled trial of 54 patients with chronic midportion Achilles tendinopathy, all doing eccentric exercises, VISA-A scores improved 21.7 points with PRP and 20.5 points with saline over 24 weeks - an adjusted between-group difference of -0.9 (95% CI -12.4 to 10.6), excluding the predefined relevant difference of 12 points. PRP added nothing to eccentric loading.

   de Vos RJ, Weir A, van Schie HT, et al. — Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA, 2010. DOI: 10.1001/jama.2009.1986.

3. A 24-site, 240-patient participant-blinded randomized trial of a single intratendinous PRP injection versus a sham (subcutaneous dry needle) for chronic midportion Achilles tendinopathy found VISA-A scores of 54.4 versus 53.4 at six months (adjusted mean difference -2.7; 95% CI -8.8 to 3.3) against a 12-point minimal clinically important difference. The authors stated the findings do not support the use of this treatment for chronic midportion Achilles tendinopathy.

   Kearney RS, Ji C, Warwick J, et al. — Effect of Platelet-Rich Plasma Injection vs Sham Injection on Tendon Dysfunction in Patients With Chronic Midportion Achilles Tendinopathy: A Randomized Clinical Trial. JAMA, 2021. DOI: 10.1001/jama.2021.6986.

4. A 12-centre randomized controlled trial of 230 patients with chronic lateral epicondylar tendinopathy compared tendon needling with leukocyte-enriched PRP against tendon needling alone. At 12 weeks there was no significant difference (55.1% versus 47.4% pain improvement; P=.163). At 24 weeks the PRP group reported 71.5% versus 56.1% pain improvement (P=.019), a 83.9% versus 68.3% success rate (P=.037), and significantly less residual elbow tenderness (29.1% versus 54.0%; P=.009). No significant complications occurred in either group.

   Mishra AK, Skrepnik NV, Edwards SG, et al. — Efficacy of platelet-rich plasma for chronic tennis elbow: a double-blind, prospective, multicenter, randomized controlled trial of 230 patients. American Journal of Sports Medicine, 2014. DOI: 10.1177/0363546513494359.

5. The devices used to spin PRP at the point of care are cleared by FDA as clinical centrifuges, product code JQC, a Class I device under 21 CFR 862.2050 - for example the Biomet GPS Platelet Separation Kit (K030555, cleared 2003) and the Harvest SmartPrep2 / SmartPrep Platelet Concentration System (K103340, cleared 2010). That clearance covers the equipment that separates blood. It is not an FDA approval of platelet-rich plasma as a treatment for osteoarthritis, tendinopathy or any other orthopedic condition, and copy must never blur the two.

   U.S. Food and Drug Administration (Center for Devices and Radiological Health) — 510(k) Premarket Notification database and Product Classification: JQC, Centrifuges (Micro, Ultra, Refrigerated) For Clinical Use, 21 CFR 862.2050. FDA accessdata (CDRH device databases), 2003.

6. Medicare's national coverage policy covers autologous platelet-rich plasma ONLY for patients with chronic non-healing diabetic, pressure and/or venous wounds, and only within an approved coverage-with-evidence-development clinical study. There is no Medicare national coverage for PRP in osteoarthritis or tendinopathy, which is why these injections are billed to the patient as cash-pay.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2024.